Belvedere Trading LLC Viking Therapeutics, Inc. Call Options Transaction History

Belvedere Trading LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Oct 30, 2024	SELL	$49.84 - $70.47 $4,984 - $7,047	-100 Reduced 1.28%	7,700 $487,000
Q2 2024 Nov 01, 2024	BUY	$47.39 - $80.2 $4,739 - $8,020	100 Added 1.3%	7,800 $413,000
Q2 2024 Aug 09, 2024	SELL	$47.39 - $80.2 $71,085 - $120,300	-1,500 Reduced 16.13%	7,800 $413,000
Q1 2024 May 09, 2024	BUY	$17.4 - $94.5 $85,260 - $463,050	4,900 Added 111.36%	9,300 $762,000
Q4 2023 Feb 13, 2024	SELL	$9.24 - $19.64 $32,340 - $68,740	-3,500 Reduced 44.3%	4,400 $81,000
Q3 2023 Oct 27, 2023	SELL	$10.92 - $16.0 $82,992 - $121,600	-7,600 Reduced 49.03%	7,900 $87,000
Q2 2023 Aug 08, 2023	BUY	$14.84 - $24.79 $32,648 - $54,538	2,200 Added 16.54%	15,500 $251,000
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $63,832 - $136,907	-7,900 Reduced 37.26%	13,300 $221,000
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $57,664 - $199,280	21,200 New	21,200 $199,000

474

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.18B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Belvedere Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Belvedere Trading LLC with notifications on news.